Cipla share price declines up to 5%; what you need to know on Wednesday, January 7

The stock came under selling pressure amid news reports that the US Food and Drug Administration (FDA) has released details of its observations on the company's Pharmathen International.

Cipla has partnered with Greece-based contract manufacturing organisation Pharmathen to commercialise the cancer drug Lanreotide in the US market, and the regulatory action has impacted investor sentiment.

Cipla: Recent updates

In December 2025, Cipla said it had partnered with Stempeutics Research to launch Ciplostem, a therapy for knee osteoarthritis approved by the Drug Controller General of India (DCGI).

Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III knee OA and marks a significant advancement in Cipla's entry into orthobiologic medicine, the Mumbai-based drugmaker said in a statement.

Knee OA is a chronic, progressive degenerative joint disease affecting more than 48.4 million people in India as of 2021, with a rising prevalence even among younger populations.

Current standard treatments primarily offer short-term relief through painkillers, viscosupplementation, or physiotherapy, often leaving a critical unmet need for therapies that target disease progression.

In December itself, Cipla launched a medication for managing obesity and type 2 diabetes mellitus.

The company has launched Yurpeak (tirzepatide), a once-weekly injectable therapy for obesity and type-2 diabetes mellitus, two of the country's most pressing health challenges, the Mumbai-based drugmaker said in a regulatory filing.

The company has the rights to distribute and promote Yurpeak -- the second brand of Lilly's tirzepatide in India – after Lilly received DCGI approval, it added.

Tirzepatide is the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults.